Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study

• Main Authors: Rozita Doosti (Author), Abdorreza Naser Moghadasi (Author), Amir Reza Azimi (Author), Shahrokh Karbalai Saleh (Author), Masoud Etemadifar (Author), Vahid Shaygannejad (Author), Fereshteh Ashtari (Author), Mohammad Hossein Harirchian (Author), Bahaadin Siroos (Author), Hormoz Ayramloo (Author), Nastaran Majdinasab (Author), Seyyed Mohammad Masood Hojjati (Author), Nabiollah Asghari (Author), Seyed Mohammad Baghbanian (Author), Hamed Cheraghmakani (Author), Mahmoud Abedini (Author), Behnaz Sedighi (Author), Negar Mohseni Abbas abadi (Author), Maedeh Ghasemitabar (Author), Sara Talebianpour (Author), Tohid Babayi Daylari (Author), Vahid Dana (Author), Neda Ghaleh noie (Author), Mohammad Ali Sahraian (Author)
• Format: Book
• Published: Babol University of Medical Sciences, 2021-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Fingolimod was the first oral therapy approved for treating relapsing-remitting multiple sclerosis (RRMS) in 2010. This open-label study evaluated the safety and efficacy of fingolideR, 0.5 mg in Iranian MS patients during one-year follow-up. Methods: A multicenter, open-label, longitudi...